VivoSim Labs
Update in progressVIVS (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that tests drugs and candidates in 3D human liver and intestinal tissue models. It provides toxicology insights, mechanism-of-action elucidation, and bespoke investigational toxicology services using novel approach methodologies. The firm offers predictive liver toxicity screening, intestinal side-effect profiling, and high-throughput, bioprinted, flow/stretch-capable tissue platforms. Formerly Organovo Holdings, it was renamed in 2025, and is based in San Diego, CA.
Company score
- Sentiment
- 0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.17
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.16
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- Founded2007
- Employees15
- Websitevivosim.ai
Identifiers
- ISINUS68620A3023
- FIGIBBG001M8GFD0